Theravance Biopharma Inc (0TB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theravance Biopharma Inc (0TB) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.51 Million ≈ $-7.61 Million USD) by net assets (€232.68 Million ≈ $272.03 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Theravance Biopharma Inc (0TB) liquidity interval to measure how many days the company can operate on defensive assets alone.
Theravance Biopharma Inc - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Theravance Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theravance Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theravance Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
China Railway Signal & Communication Corporation Limited
F:RS3
|
0.008x |
|
Raisecom Technology Co Ltd
SHG:603803
|
-0.004x |
|
Lighthouse Capital Ltd
JSE:LTE
|
0.026x |
|
Coretronic
TWO:5371
|
0.016x |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
0.038x |
|
Koppers Holdings Inc
NYSE:KOP
|
0.084x |
|
Heritage Commerce Corp
NASDAQ:HTBK
|
0.028x |
|
Grupo Supervielle SA
NYSE:SUPV
|
0.118x |
Annual Cash Flow Conversion Efficiency for Theravance Biopharma Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of Theravance Biopharma Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Theravance Biopharma Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €175.54 Million ≈ $205.23 Million |
€-11.54 Million ≈ $-13.49 Million |
-0.066x | +48.16% |
| 2023-12-31 | €213.00 Million ≈ $249.01 Million |
€-27.00 Million ≈ $-31.56 Million |
-0.127x | +70.05% |
| 2022-12-31 | €441.80 Million ≈ $516.51 Million |
€-186.99 Million ≈ $-218.61 Million |
-0.423x | -168.94% |
| 2021-12-31 | €-338.57 Million ≈ $-395.83 Million |
€-207.86 Million ≈ $-243.01 Million |
0.614x | -25.53% |
| 2020-12-31 | €-303.75 Million ≈ $-355.12 Million |
€-250.40 Million ≈ $-292.75 Million |
0.824x | -22.53% |
| 2019-12-31 | €-223.84 Million ≈ $-261.69 Million |
€-238.20 Million ≈ $-278.48 Million |
1.064x | -51.36% |
| 2018-12-31 | €-51.59 Million ≈ $-60.31 Million |
€-112.87 Million ≈ $-131.95 Million |
2.188x | +225.33% |
| 2017-12-31 | €115.18 Million ≈ $134.66 Million |
€-201.05 Million ≈ $-235.05 Million |
-1.746x | -517.60% |
| 2016-12-31 | €350.23 Million ≈ $409.46 Million |
€-98.99 Million ≈ $-115.73 Million |
-0.283x | +59.31% |
| 2015-12-31 | €243.06 Million ≈ $284.17 Million |
€-168.86 Million ≈ $-197.41 Million |
-0.695x | -14.94% |
| 2014-12-31 | €289.79 Million ≈ $338.79 Million |
€-175.16 Million ≈ $-204.77 Million |
-0.604x | -- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more